11 active not recruiting. 11 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Active not recruiting 11 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow Primary Dysautonomias: new trials by email Literature Review of Primary Dysautonomias trials Research Report on Primary Dysautonomias
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Restoring Iron Deficiency in POTS Intravenous iron - POTS - Postural Orthostatic Tachycardia Syndrome | Phase 2 | Active not recruiting | Vanderbilt University Medical Center | 12 | 2025-11-24 | 2026-10-13 |
| A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy YA-101, Placebo - Multiple System Atrophy | Phase 2 | Active not recruiting | Dasher Neuroscience Inc. | 75 | 2025-03-03 | 2026-08-19 |
| A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy TEV-56286, Placebo - Multiple System Atrophy | Phase 2 | Active not recruiting | Teva Branded Pharmaceutical Products R&D LLC | 349 | 2024-10-02 | 2026-10-09 |
| SalT Supplementation in Older Adults With Orthostatic Intolerance Disorders Salt supplementation (encapsulated sodium chloride) - Orthostatic Hypotension | Phase 2 | Active not recruiting | University of Galway | 42 | 2024-07-09 | 2026-06-22 |
| Pilot Study of Dexmedetomidine Sublingual Film for the Ambulatory Treatment of Hyperadrenergic Autonomic Crisis in Patients With Familial Dysautonomia Dexmedetomidine Sublingual - Familial Dysautonomia | Phase 2 | Active not recruiting | NYU Langone Health | 5 | 2024-06-01 | 2026-03-04 |
| A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy ONO-2808, Placebo - Multiple System Atrophy (MSA) | Phase 2 | Active not recruiting | Ono Pharmaceutical Co., Ltd. | 92 | 2023-09-22 | 2026-10-06 |
| Terazosin and Parkinson's Disease Extension Study Terazosin therapy - Symptomatic Parkinson Disease, REM Sleep Behavior Disorder | Phase 2 | Active not recruiting | Cedars-Sinai Medical Center | 15 | 2022-09-23 | 2026-03-02 |
| Randomized Double-Blind Placebo-Controlled Adaptive Design Trial Of Intrathecally Administered Autologous Mesenchymal Stem Cells In Multiple System Atrophy Autologous Mesenchymal Stem Cells, Placebo - Multiple System Atrophy | Phase 2 | Active not recruiting | Mayo Clinic | 71 | 2021-12-15 | 2026-06-12 |
| A Study of Lu AF82422 in Participants With Multiple System Atrophy Lu AF82422, Placebo - Multiple System Atrophy | Phase 2 | Active not recruiting | H. Lundbeck A/S | 64 | 2021-11-16 | 2026-04-13 |
| Adrenergic Blockers for Cardiac Changes in Early Parkinson's Disease (Protocol 53136) Carvedilol - REM Sleep Behavior Disorder, Pre-motor Parkinson Disease | Phase 2 | Active not recruiting | Michele Tagliati, MD | 15 | 2019-04-04 | 2026-03-02 |
| Treatment of Orthostatic Intolerance Acetazolamide, Atomoxetine, NO Drug - Tachycardia, Chronic Orthostatic Intolerance | Phase 1 / Phase 2 | Active not recruiting | Satish R. Raj | 150 | 1997-04-01 | 2026-10-16 |
Multiple System Atrophy (5) · Nerve Degeneration (2) · Parkinson Disease (2) · Parkinson Disease, Secondary (2) · Postural Orthostatic Tachycardia Syndrome (2) · REM Sleep Behavior Disorder (2) · Dysautonomia, Familial (1) · Hypotension, Orthostatic (1) · Iron Deficiencies (1) · Neurodegenerative Diseases (1) · Pure Autonomic Failure (1) · Tachycardia (1) · Tachycardia, Sinus (1)
Autonomic Nervous System Diseases (11) · Nervous System Diseases (11) · Basal Ganglia Diseases (7) · Brain Diseases (7) · Central Nervous System Diseases (7) · Movement Disorders (7) · Neurodegenerative Diseases (7) · Synucleinopathies (7) · Orthostatic Intolerance (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Cardiovascular Diseases (2) · Mental Disorders (2) · Parasomnias (2)
3-(1,3-benzodioxol-5-yl)-5-(3-bromophenyl)-1H-pyrazole (1) · Acetazolamide (1) · Atomoxetine Hydrochloride (1) · Carvedilol (1) · Clonidine (1) · Dexmedetomidine (1) · Drinking Water (1) · Indomethacin (1) · Isosorbide Dinitrate (1) · Mecamylamine (1) · Melatonin (1) · Memantine (1) · Midodrine (1) · Modafinil (1) · Octreotide (1)
Cedars-Sinai Medical Center (1) · Dasher Neuroscience Inc. (1) · H. Lundbeck A/S (1) · Mayo Clinic (1) · Michele Tagliati, MD (1) · NYU Langone Health (1) · Ono Pharmaceutical Co., Ltd. (1) · Satish R. Raj (1) · Teva Branded Pharmaceutical Products R&D LLC (1) · University of Galway (1) · Vanderbilt University Medical Center (1)
United States (10) · Japan (4) · France (1) · Germany (1) · Ireland (1) · Israel (1) · Italy (1) · Serbia (1) · Spain (1) · Taiwan (1)
Michele Tagliati, MD, FAAN (2) · Alejandra Gonzalez-Duarte, MD (1) · Andrew Smyth (1) · Catriona Reddin (1) · Italo Biaggioni, MD (1) · Martin O'Donnell (1) · Project Leader (1) · Satish R Raj, MD MSCI (1) · Wolfgang Singer, MD (1)
PMID 10214756, PMID 10406987, PMID 10527042, PMID 10853813, PMID 10979878, PMID 11076832, PMID 11400186, PMID 11724917, PMID 12498954, PMID 12904089, PMID 15175402, PMID 15345186, PMID 15645531, PMID 15779234, PMID 15911704, PMID 16025231, PMID 16442563, PMID 16715205, PMID 16837857, PMID 17190953, PMID 18079166, PMID 18349024, PMID 19018276, PMID 19687359, PMID 20146689, PMID 20188504, PMID 20846908, PMID 20887968, PMID 20976736, PMID 21045744, PMID 21421334, PMID 21538520, PMID 21571570, PMID 21700495, PMID 21802993, PMID 22321865, PMID 22483040, PMID 22508280, PMID 23024438, PMID 23160999, PMID 23266935, PMID 23329524, PMID 23347909, PMID 23562390, PMID 23647842, PMID 23970363, PMID 24002370, PMID 24227635, PMID 24332912, PMID 24495468
2023 (1), UL1TR000445 (1)